PROF Keeps the Bull Case Alive-But Q2 Revenue Still Fails the Smell Test

Orders Are Up, but the Income Statement Still Says "Not Yet"

The setup is straightforward. After Q2 earnings released on Aug. 6, investors got both sides of the story: some signs that demand is holding up, but also another quarter that fell short on reported results. Q2 sales of $2.483 million and Q2 EPS of -$0.26 kept the financial pressure visible. For now, the stock still depends on whether management can turn that demand into revenue at a faster pace.

What the market has to weigh

The clearest macro signal is the full-year outlook. Profound affirmed FY2026 sales guidance of $25.000 million, which keeps the longer-term target intact, even though that outlook remains below the $26.858 million estimate. Bulls can live with that for now because the company has not abandoned the target. Bears can reasonably argue that guidance is not the same as delivered revenue.

Investors do not need a perfect quarter. They need evidence that commercial activity is starting to show up in the numbers. So far, that evidence is still limited. If conversion improves, the upside case remains intact. If another few quarters look like "coming soon" rather than scaling, patience will get harder to defend.

The Product Story Holds Up, but Adoption Still Has to Show Up in Sales

The bull case only works if clinicians are choosing this over standard options, not just evaluating it. On the surface, that story is credible: it is an MRI-guided, incision-free prostate therapy that can be tailored from whole-gland to focal treatment. That kind of clinical flexibility can support adoption through referrals and repeated use if practitioners see real value.

Early adoption signals are there, but they are not proof of scale

One of the clearest practical signals is the 100th TULSA Procedure™ milestone at Texas Prostate. A hundred cases is not definitive proof of broad adoption, but it does suggest the technology has moved past the initial curiosity phase in at least one center.

The clinical backdrop helps explain why that interest could persist. Profound has highlighted CAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence. That does not settle the full efficacy debate, but in device markets, safety plus a plausible clinical benefit can be enough to build referrals and reduce hesitation.

What investors should watch next

This is still not the same as saying revenue is proving the story. It is saying the bull case has enough real-world support to remain credible. The next question is whether usage keeps compounding well enough to show up in reported results.

Watch for:

• More than one success story: additional sites reaching meaningful case volumes, rather than reliance on a single pioneer center.
• Routine use: the TULSA Procedure showing up in normal practice flow, not only in promotional or early-adopter settings.
• Stronger outcome data: more clinical readouts that move the discussion from promising to clearly beneficial.
• Faster training and credentialing: broader clinician uptake, which is usually how medical devices spread through a specialty.
• Revenue conversion: usage translating into bookings and sales soon, because that is what finally resolves the story.

What Has to Change Before Investors Pay Up for the Narrative

The next clean scoreboard check is the first quarter 2026 results on May 7, followed by the 4:30 p.m. ET conference call. That is the next clear opportunity to separate durable adoption from a compelling narrative.

What management needs to show

In plain English, the sequence should be simple: if clinicians find real value in an MRI-guided, incision-free therapy, they will use it more, and reported results should eventually reflect that. Profound's own description of TULSA-PRO as a platform designed for personalized treatment strategies from whole-gland to focal treatment gives the bull case a logical path. But the path only matters if it shows up in revenue soon.

That is why the debate is still practical rather than theoretical. Bulls can argue the product has genuine clinical utility because it lets physicians see, treat, and confirm therapy in real time. Bears can argue the product story alone does not pay the bill. For now, the more disciplined stance is to treat PROF as a watchlist setup rather than a blind buy.

Investor watchpoints

On the May 7 release and call, listen for:

• Any update on how order activity is converting into reported revenue.
• Evidence that adoption is broadening beyond a small set of early sites.
• Signs that training, credentialing, and case volumes are improving in line with management's story.

What would break the setup is easy to spot: more headlines, but still weak conversion. If the next few updates do not show that shift, patience stops being an advantage.